Page 4 - Binding Affinity News Today

Researchers performed an epidemic dynamic analysis to assess the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)’s sub-VOC XBB.1.5 characteristics.

Researchers developed a computational workflow based on molecular dynamic (MD) simulations and artificial neural network (ANN) to assess the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD)-human angiotensin-converting enzyme 2 (hACE2) binding affinities of SARS-CoV-2 variants.

Researchers investigated the reasons for the rapid advent of SARS-CoV-2 XBB.1.5, a sublineage of the Omicron recombinant mutant XBB in the USA.

Researchers isolated SARS-CoV-2 spike protein-targeted mAbs from convalescent healthcare workers, emphasizing the IGHV1-69 gene, the gene with the greatest structural and allelic variation.

Researchers characterized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BQ.1.1 sub-variant.

Researchers have developed a new computer framework that holds promise in the work to discover new drugs. Their framework uses an artificial intelligence method called convolutional neural network to provide global information about potential novel drug candidates.

A new paper examines the understanding of glycosylation in an array of rheumatic diseases and indicates the potential for therapeutic interventions using the same mechanism.

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.